<DOC>
	<DOCNO>NCT02909023</DOCNO>
	<brief_summary>Activation immune system pathogen consider one effective intervention field infectious disease . Transgene develop therapeutic vaccine `` TG1050 '' treatment patient chronic treat Hepatitis B . This biotherapy compound development T cellular immune response patient order achieve total elimination infect cell . Therefore necessary measure way assess accurately reliably presence response study subject .</brief_summary>
	<brief_title>Performance HBV ELISPOT Detection T Cellular Immune Response Patients Infected HBV Cured</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Man woman age â‰¥18 year old . Patients chronic hepatitis B regardless genotype . treat nucleotide analog approve treatment hepatitis B. untreated . positive negative antigen HBe regardless level transaminase . Patients history HBV infection ( recover ) seroconversion antigen HBs spontaneously treatment . Patient general state range 0 1 ECOG scale ( Eastern Cooperative Oncology Group ) Patient sign informed consent Patient social security affiliation patient coinfected human immunodeficiency virus ( HIV ) Hepatitis C virus ( HCV ) . Patients treat interferon , immunosuppressive , experimental treatment consist unapproved molecule treatment hepatitis B . Patient unable meet constraint study Patient transplant Patient history cancer autoimmune disease within 5 year Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>Elispot test</keyword>
	<keyword>T cellular immune response</keyword>
</DOC>